This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in
children with high-risk neuroblastoma followed by standard induction chemotherapy,
intensification with autologous stem cell transplantation, and an oral maintenance phase with
13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan
window will be efficacious.